RA
ICPT

Royce & Associates’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Royce & Associates’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-27,000
Closed -$1.57M – 1283
2017
Q3 		$1.57M Buy
+27,000
New +$2.91M 0.01% 880
2014
Q3 		– Sell
-360
Closed -$85K – 1437
2014
Q2 		$85K Buy
+360
New +$94.9K ﹤0.01% 1351

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's ICPT Position: Q4 2017 in Review

Royce & Associates sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2017, closing a stake of 27,000 shares — an estimated $1.57M sold.

Royce & Associates first reported a position in ICPT in Q2 2014 and held it in 2 quarters. The position peaked at $1.57M in Q3 2017. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2017.

  • Royce & Associates reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Royce & Associates sold 27,000 Intercept Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1.57M.
  • Royce & Associates first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
  • Royce & Associates's Intercept Pharmaceuticals, Inc. position peaked at $1.57M in Q3 2017.
  • 169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2017.

Based on Royce & Associates's 13F filing for Q4 2017, filed 9 Feb 2018.